Focus: Praxis Precision Medicines is a Boston-based biotech focused on genetic neuroscience treatments, particularly in epilepsy, developmental encephalopathies, and neuropsychiatric disorders. The company is actively scaling with 27 open positions across clinical, manufacturing, and regulatory functions.
Profile data last refreshed 44m ago · AI intelligence enriched 2w ago
Stable — net -2 jobs in 30d
12 added, 14 removed. Backfill posture.
A compelling opportunity for clinical operations, manufacturing, and regulatory professionals seeking exposure to multiple Phase 3 catalysts in rare neurology; higher risk for core R&D or discovery scientists due to lack of transparency on funding and sustainability.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Praxis Precision Medicines
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Praxis Precision Medicines's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Praxis Precision Medicines Prepares for Major FDA Decisions in 2026 - HarianBasis.co
Praxis Precision Medicines Prepares for Major FDA Decisions in 2026 HarianBasis.co
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor - ChartMill
Praxis Precision Medicines Announces FDA Acceptance of New Drug Application for Ulixacaltamide HCl in Patients with Essential Tremor ChartMill
Praxis Precision Medicines Announces FDA Acceptance of New - GlobeNewswire
Praxis Precision Medicines Announces FDA Acceptance of New GlobeNewswire
FDA starts Praxis review for essential tremor drug, decision due Jan. 2027 - Stock Titan
FDA starts Praxis review for essential tremor drug, decision due Jan. 2027 Stock Titan
FDA accepts Praxis (PRAX) ulixacaltamide NDA for adult essential tremor - Stock Titan
FDA accepts Praxis (PRAX) ulixacaltamide NDA for adult essential tremor Stock Titan
In a nine-patient Praxis trial, children had 77% fewer seizures - Stock Titan
In a nine-patient Praxis trial, children had 77% fewer seizures Stock Titan
Showing 6 of 10 news items
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moBased on last 4 crawl cycles